[News Brief] EDDC Partners Daiichi Sankyo on NK Cell Cancer Therapy

Singapore’s Experimental Drug Development Centre (EDDC) has entered a research collaboration with Daiichi Sankyo to develop next-generation NK cell engagers (NKCEs) aimed at improving cancer immunotherapy outcomes.

• Research Focus: Preclinical programme to design and evaluate novel NKCEs with enhanced anti-tumour activity and reduced systemic inflammatory responses.
• Technology: NKCEs aim to direct natural killer cells to better identify and eliminate cancer cells.
• Objective: Address limitations of current immunotherapies, including toxicity and durability, through improved biologics and engineering approaches.

This summary is based on a news article by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.